BMC Nephrology最新文献

{"title":"Polycythemia secondary to bilaterally enlarged kidneys in T-Cell acute lymphoblastic leukemia: a case report and literature review.","authors":"Koji Yoshimoto, Yujiro Maeoka, Shiori Kubota, Ren Chishaki, Akira Takahashi, Yosuke Osaki, Tatsuji Mino, Tatsuo Ichinohe, Takao Masaki","doi":"10.1186/s12882-025-04032-3","DOIUrl":"10.1186/s12882-025-04032-3","url":null,"abstract":"<p><strong>Background: </strong>Polycythemia is a rare disease that can cause hypertension. Secondary polycythemia with increased production of erythropoietin (EPO) is associated with several kidney diseases, including hydronephrosis and cystic disease. However, there have been no reports of a case presenting with polycythemia secondary to bilateral nephromegaly caused by renal infiltration of T-cell acute lymphoblastic leukemia (T-ALL).</p><p><strong>Case presentation: </strong>A 32-year-old Japanese man presented with marked hypertension (215/150 mmHg) with renal insufficiency (creatinine 3.7 mg/dL), proteinuria, hematuria, bilateral nephromegaly, polycythemia (hemoglobin 20.2 g/dL), and increased serum EPO (38.7 mIU/mL, range 4.2-23.7 mIU/mL). Based on renal and bone marrow biopsy findings, he was diagnosed with T-ALL and bilaterally enlarged kidneys caused by renal infiltration of leukemic cells. There was no evidence of endocrine hypertension or fluid retention. Remission induction chemotherapy led to a decrease in kidney size, hemoglobin levels, and serum EPO levels, and allowed dose reductions of most hypertensive drugs, suggesting that hypertension was secondary to polycythemia. The patient's renal function gradually improved and hemodialysis was discontinued after 1 month of chemotherapy.</p><p><strong>Conclusions: </strong>We report a case of marked hypertension and secondary polycythemia induced by severe renal infiltration of T-ALL at diagnosis, which were synchronically improved with induction chemotherapy. This case history suggests the importance of considering lymphoproliferative diseases in the differential diagnosis of secondary polycythemia, leading to severe hypertension.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"121"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats.","authors":"Zhaoli Gao, Yanxia Gao, Qiang Wang, Qi Wang, Peng Lu, Hailin Lv, Haoran Xue, Xiaotian Ma, Shuen Li, Zhao Hu","doi":"10.1186/s12882-025-04045-y","DOIUrl":"https://doi.org/10.1186/s12882-025-04045-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Roxadustat is a novel hypoxia- inducible factor-prolyl hydroxylase inhibitor(HIF-PHI) used to treat anemia in chronic kidney disease (CKD) patients. It has been reported that roxadustat can slow down kidney damage and delay the development of kidney fibrosis. Anemia and iron deficiency are often associated with the vast majority CKD patients, and insufficient available iron or total iron storage is often the most common cause of anemia and ESAs resistance in CKD patients. The role of iron availability in the pathogenesis of anemia in chronic kidney disease has received increasing attention.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;To explore whether combined roxadustat and polysaccharide-iron complex (PIC) is more successful than standalone roxadustat, the appropriate iron supplement dosage and mechanism of roxadustat in the treatment of CKD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;Healthy male Sprague Dawley rats were randomly divided into two groups: the control (NC) group which were sham-operated and the CKD group. The CKD group was given an adenine diet for three weeks after right unilateral nephrectomy and further divided into 6 groups: the CKD only, CKD + PIC, CKD + Roxa, CKD + PIC (25 mg/kg) + Roxa, CKD + PIC (50 mg/kg) + Roxa, and CKD + PIC (75 mg/kg) + Roxa groups. The sham-operated rats receiving only standard diet served as the control group. Roxadustat were administrated intragastrically at 10 mg/kg thrice per week in groups with Roxa. The hemoglobin (Hb), reticulocyte hemoglobin equivalent (RET-He), reticulocyte % (RET%), plasma urea nitrogen (BUN), plasma creatinine (Cr), serum iron (SI), Total iron binding capacity (TIBC), serum hepcidin-25, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL- 1β), and High mobility group protein B1 (HMGB1) levels of each group of rats were assessed. Masson staining was used to evaluate renal fibrosis, and quantitative real-time Polymerase Chain Reaction (RT-PCR) was used to detect the mRNA expression of alpha-smooth muscle actin (α-SMA) and Fibronectin (Fn) in rat renal tissues to further evaluate renal fibrosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Level of Hb in the CKD + PIC (75 mg/kg) + Roxa group increased the fastest, roxadustat combined with PIC in the treatment of renal anemia was significantly more effective than Roxadustat or PIC alone. On day 105, in the CKD + PIC (75 mg/kg) + Roxa group, there was a significant decrease in BUN and Cr levels compared to the CKD only group (p &lt; 0.05). Roxadustat reduces the level of hepcidin, IL-6, TNF-α, IL-1β and HMGB1in CKD rats. (p &lt; 0.05). Roxadustat alleviates renal fibrosis in CKD rats (p &lt; 0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;HIF-PHI combined with iron supplement (Roxadustat combined with PIC) has an improved effect on the treatment of renal anemia, and early administration of sufficient iron enables the Hb to rise rapidly. Early administration of adequate dose of PIC is necessary for renal a","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"125"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome.","authors":"Omri Feder, Dana Amsterdam, Mohamad Ershed, Ayelet Grupper, Doron Schwartz, Orit Kliuk-Ben Bassat","doi":"10.1186/s12882-025-04035-0","DOIUrl":"https://doi.org/10.1186/s12882-025-04035-0","url":null,"abstract":"<p><strong>Background: </strong>Corticosteroids are highly efficient for treatment of minimal change disease (MCD), however a substantial number of patients become steroid dependent (SD) or frequent relapsing (FR). Response rate is lower in primary Focal Segmental Glomerulosclerosis (FSGS). Since prolonged exposure to corticosteroids should be avoided, an effective alternative is required. Rituximab is a promising agent. We aimed to evaluate the efficacy of Rituximab in adults with SD/FR nephrotic syndrome (NS).</p><p><strong>Methods: </strong>A retrospective cohort study, evaluating patients with SD/FR NS treated with Rituximab in a tertiary hospital. Rituximab was given at induction, with additional doses subjected to the treating nephrologist decision. Primary outcome was number of relapses and time to first relapse. Safety was assessed.</p><p><strong>Results: </strong>Twenty-one adults were included. Among them, 14 (66.7%) were diagnosed with MCD, 5 (23.8%) with FSGS, in 2 cases kidney biopsies were not performed. Median age was 54.6 years. Median follow up was 39.6 months. Number of relapses decreased significantly after Rituximab compared to before treatment (median relapses 0 compared to 3, respectively, W = 3.70, p <.001). Time to first relapse was significantly shorter before Rituximab compared to after (median 11 vs. 536 days, respectively, W = 3.05, p =.002). Hazzard Ratio for relapse was higher in patients who received one Rituximab course compared to those who received an additional maintenance (HR = 4.31, 95% CI: 1.13-16.39, p =.032). Treatment was well-tolerated, serious adverse events included cholecystitis and severe COVID-19.</p><p><strong>Conclusions: </strong>Rituximab emerges as an efficient safe steroid sparing in patients with SD/FR NS, with longer remission achieved when an additional maintenance dose is given after the first course.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"126"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in training and practice in tunnelled haemodialysis catheter removal: a survey of nephrology trainees across United Kingdom.","authors":"Ismet Boral, Shalabh Srivastava, Joanna McKinnell","doi":"10.1186/s12882-025-04034-1","DOIUrl":"https://doi.org/10.1186/s12882-025-04034-1","url":null,"abstract":"<p><strong>Background: </strong>The tunnelled haemodialysis catheter (TDC) removal is a necessary skill for the nephrology trainee as this task is undertaken routinely in renal units. Little published data exists to establish current practice and there is no national guidance regarding TDC removal in United Kingdom (UK). Anecdotally, trainees suggest they do not have sufficient supervised training in TDC removal. We aimed to establish the differences in training and practice in TDC removal among nephrology trainees across UK.</p><p><strong>Method: </strong>We created an online survey with twenty questions for trainee and non-training nephrology registrars working in UK. The survey was distributed via regional renal training programme directors, UK Kidney Association, \"Renal SpR Club\" and online professional social networks including social media and instant messaging services.</p><p><strong>Results: </strong>We received 75 responses from all of 14 postgraduate training deaneries. 91% reported renal registrars remove TDCs in their units. 53% of the operators were taught by another registrar. Only 16% report awareness of written local trust guidance on TDC removal. 43% reported removing > 10 TDCs a year. Cut-down method is preferred over traction method for TDC removal. 63% remove TDCs in designated procedure areas, 52% obtain written consent and 65% wear full sterile personal protective equipment (PPE). 16% report removing TDCs alone with no assistant and 12% do not stop aspirin, antiplatelets or anticoagulants beforehand. 30% of operators reported experiencing a \"stuck catheter\" at some point in their careers.</p><p><strong>Conclusions: </strong>This survey highlights that TDC removal is a common procedure and predominantly performed by renal physicians in teaching hospitals. It is mostly undertaken by registrar level doctors often without formal training or written guidelines with varying techniques. 68% of participants want this procedure to be part of mandatory training in the renal post graduate training curriculum.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"124"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of low-protein diet on residual renal function in dialysis patients: a systematic review and metaanalysis.","authors":"Jingyi Xie, Xiaoqin Liu, Yue Ling, Shuwang Ge, Ying Yao","doi":"10.1186/s12882-025-04042-1","DOIUrl":"https://doi.org/10.1186/s12882-025-04042-1","url":null,"abstract":"<p><strong>Objective: </strong>A low-protein diet is essential for the nutritional management of chronic kidney diseases as it can reduce renal burden. However, the effect of low-protein diets on dialysis patients compared to pre-dialysis patients remains unclear. This study aims to compare residual renal function among dialysis patients following a low-protein diet versus a normal diet, offering valuable insights into the optimal nutritional strategy for preserving residual renal function.</p><p><strong>Methods: </strong>This meta-analysis has been registered on PROSPERO, an international registry of prospective systematic reviews. We conducted a comprehensive and systematic literature search using PubMed, Cochrane Library and Web of Science (WOS). Our search strategy was designed to discover all relevant studies investigating the influence of low-protein diets on residual renal function among dialysis patients. Four studies met the inclusion criteria. Heterogeneity was discussed through subgroup analysis of dialysis method, the addition of ketoacid and other relevant factors.</p><p><strong>Results: </strong>We included four prospective studies of low-protein diets among dialysis patients, each of which included at least 40 participants. Individuals receiving a 12-months low-protein diet had a higher GFR (MD = 1.37 ml/min; 95% CI:0.18 to 2.55), while daily urine volume decreasing more slowly (MD = 660 ml; 95% CI: 110 to 1210). In addition, dialysis patients undergoing a low-protein diet for 4 or 12 months had reduced serum phosphorus (MD=-0.74 g/dl; 95% CI: -1.04 to -0.45). Their serum albumin was higher than dialysis patients received a free-choice diet (MD = 4.00 g/dl; 95% CI: 2.46 to 5.54).</p><p><strong>Conclusion: </strong>Dialysis patients who adhere to a long-term low-protein diet may have a positive effect on residual kidney function. In addition, dialysis patients receiving a low-protein diet increased serum albumin, reduced serum phosphorus levels, and maintained a better nutritional status and electrolyte balance.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"122"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of uric acid to high-density lipoprotein cholesterol ratio with the presence or absence of hypertensive kidney function: results from the China Health and Retirement Longitudinal Study (CHARLS).","authors":"Siying Li, Zhen Liu, Chen Lu","doi":"10.1186/s12882-024-03939-7","DOIUrl":"https://doi.org/10.1186/s12882-024-03939-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Some studies have shown that uric acid (UA) to high-density lipoprotein (HDL-C) ratio (UHR), as an indicator of inflammation, is associated with metabolic syndrome and hypertension, but its relationship with decreased renal function is unclear. This study intends to analyze the relationship between UHR and decline in renal function.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data were obtained from the 2011-2015 data of the China Health and Aging Tracking Survey (CHARLS) of Peking University, and 7,198 study participants were included and followed up until 2015. The eGFR (Total glomerular filtration rate) was estimated according to the CKD-EPI [1] creatinine equation. eGFR ≥ 60mL/min/1.73 m² at baseline renal function was defined as normal renal function, and eGFR &lt; 60mL/min/1.73 m² at baseline renal function was defined as chronic kidney disease; new-onset eGFR &lt; 60mL/min/1.73 m² was defined as the occurrence of decline in renal function; in the chronic kidney disease population decrease in eGFR ≥ 5mL/min/1.73 m²/year or 30% from baseline or admission to dialysis was defined as rapid progression of chronic kidney disease. eGFR slope was defined as the ratio of the difference between the final eGFR and the baseline eGFR over 4 years of follow-up. Binary logistic regression was used to analyze the relationship between UHR and renal function decline or progression, as well as linear regression and non-linear regression to clarify the relationship between UHR and GFR slope in hypertensive patients, and the correlation between UHR and CRP, and to assess the relationship between UHR levels and the risk of renal function decline in hypertensive people.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;(1) Hypertension was a risk factor for the decline of renal function (OR: 1.34, P = 0.03); (2) UHR was a risk factor for the decline of renal function in the hypertensive population (OR: 1.32, P = 0.02), and with the increasing level of UHR, the risk of developing CKD (Chronic Kidney Disease) in hypertension was higher (P for trend = 0.03); (3) The subgroup analyses showed that there was no interaction between hypertension and age, cystatin C and hemoglobin did not interact with each other; (4), In the hypertensive population, the slope of UHR and eGFR showed a J-shaped correlation, with UHR &gt; 7.6% as the cut-off point, and the slope of eGFR tended to increase with increasing UHR; in the non-hypertensive population UHR and eGFR showed a linear correlation, and the slope of the decline in eGFR was smaller than that of the hypertensive population; (5), After adjusting for confounders, UHR and CRP were positive correlation (t = 3.56, P &lt; 0.05); (6) In the hypertensive population with normal CRP, the risk of decline in renal function increased accordingly with increasing UHR (P = 0.003). UHR did not show a correlation with CRP in the hypertensive population with abnormal CRP (P = 0.24).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In the hypertensive population, elev","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"123"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the diagnosis of early biomarkers for acute kidney injury: a literature review.","authors":"Hongsha Yang, Yanqin Chen, Jiajia He, Yi Li, Yunlin Feng","doi":"10.1186/s12882-025-04040-3","DOIUrl":"10.1186/s12882-025-04040-3","url":null,"abstract":"<p><p>Acute kidney injury (AKI) is a critical condition with diverse manifestations and variable outcomes. Its diagnosis traditionally relies on delayed indicators such as serum creatinine and urine output, making early detection challenging. Early identification is essential to improving patient outcomes, driving the need for novel biomarkers. Recent advancements have identified promising biomarkers across various biological processes. Tubular injury markers, including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), N-acetyl-β-D-glucosaminidase (NAG), and liver-type fatty acid-binding protein (L-FABP), offer insights into early tubular damage. Inflammatory and repair-associated biomarkers, such as interleukin-18 (IL-18), monocyte chemotactic protein-1 (MCP-1), osteopontin (OPN), and C-C motif chemokine ligand 14 (CCL14), reflect ongoing injury and recovery processes. Additionally, stress and repair markers like tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein-7 (IGFBP-7), alongside filtration markers such as cystatin C (CysC) and proenkephalin (PenKid^®) e.tal, further enhance diagnostic precision. Oxidative stress-related markers, including Superoxide Dismutase 1 (SOD1), also contribute valuable information. Emerging candidates, such as microRNAs, soluble urokinase plasminogen activator receptor (SuPAR), and chitinase-3-like protein 1 (CHI3L1), hold substantial promise for AKI detection and prognosis. This review summarizes the progress in AKI biomarker research, highlighting their clinical utility and exploring their potential to refine early diagnosis and management strategies. These findings offer a new perspective for integrating novel biomarkers into routine clinical practice, ultimately improving AKI care.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"115"},"PeriodicalIF":2.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary energy intake predicts mortality in Chinese patients with peritoneal dialysis: a single-center 18 years' follow-up study.","authors":"Su-Xuan Liu, Ke Xu, Meng-Yuan Lu, Xiao-Qing Zhang, Chun-Yan Su, Wen Tang","doi":"10.1186/s12882-025-04051-0","DOIUrl":"10.1186/s12882-025-04051-0","url":null,"abstract":"<p><strong>Background: </strong>Lower dietary energy intake (DEI) may be associated with increased mortality risk. This study aims to analyze the influence of baseline DEI, time average DEI, and other factors on survival in peritoneal dialysis (PD) patients.</p><p><strong>Method: </strong>It was a single-center retrospective cohort study. Patients who started PD from January 2006 to June 2021 were included in this study and followed up until June 2023. Their baseline (six months after the beginning of PD) demographic, dietary intake, laboratory data, and time varying dietary intake data were collected and analyzed. The relationships between these data and survival were examined using Cox model to estimate death hazard ratios.</p><p><strong>Result: </strong>A total of 794 patients were included in this study, 424 males and 370 females, with a mean age of 58.87 ± 16.02 years. Their mean normalize baseline dietary energy intake (nDEI) was 25.46 ± 6.72 kcal/kg/day, time average nDEI was 24.87 ± 4.74 kcal/kg/day. The median follow-up duration was 46.58 (27.38, 78.52) months in the overall cohort. Based on multivariate Cox proportional hazard analysis, age (HR = 1.056, 95% Cl = 1.047-1.065, p < 0.001), diabetes (HR = 1.364, 95% Cl = 1.114-1.671, p = 0.003), serum albumin (HR = 0.945, 95% Cl = 0.923-0.967, p < 0.001), blood sodium (HR = 0.973, 95% Cl = 0.954-0.992, p = 0.002), serum urea (HR = 0.974, 95% Cl = 0.953-0.994, p = 0.025), and baseline nDEI (HR = 0.980, 95% Cl = 0.964-0.996, p = 0.017) were significantly associated with mortality. Baseline DPI, BMI and time average nDEI were not related to PD patients' survival. When classified baseline nDEI into 4 groups (< 25 kcal/kg/day, 25-29.99 kcal/kg/day, 30-34.99 kcal/kg/day, and ≥ 35 kcal/kg/day), the univariate and multivariate Cox proportional hazard analysis showed that the patients with nDEI 30-34.99 kcal/kg/day had the lowest mortality risk (using the DEI < 25 kcal/kg/day group as reference, p < 0.05).</p><p><strong>Conclusion: </strong>Our study revealed that DEI 30-34.99 kcal/kg/day might be beneficial to the long-term outcome for the Chinese PD population.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"120"},"PeriodicalIF":2.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Podocyturia an emerging biomarker for kidney injury.","authors":"Charbel Hanna, Hady El Etry, Maroun Ibrahim, Lynn Khalife, Sola Aoun Bahous, Wissam H Faour","doi":"10.1186/s12882-025-04039-w","DOIUrl":"10.1186/s12882-025-04039-w","url":null,"abstract":"<p><p>Podocyte injury is an established hallmark of kidney disease progression. Podocyte loss is a widely proven hypothesis to explain, in part, glomerular damage. Regardless of the underlying kidney disease, the pathophysiologic processes frequently involve the glomerulus. A growing body of evidence considered that podocytes detachment (podocytopathy) and their presence in the urine (podocyturia) are the hallmark of glomerular disease progression. As such, developing new tools to monitor disease progression non-invasively is of major clinical importance. Detection of podocytes in the urine as a biomarker of disease progression would be a major achievement toward the development of such tools. This review summarizes current knowledge about podocyturia.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"118"},"PeriodicalIF":2.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and influencing factors of social participation in patients undergoing maintenance haemodialysis: a Cross-sectional study following the international classification of functioning, disability, and health framework.","authors":"W W Ge, H L Zhang, P Liu, L X Yin","doi":"10.1186/s12882-025-04044-z","DOIUrl":"10.1186/s12882-025-04044-z","url":null,"abstract":"<p><strong>Background: </strong>Maintenance haemodialysis (MHD) has emerged as a primary treatment modality in individuals with end-stage kidney disease. However, haemodialysis not only affects physiological well-being but also significantly influences patients' social engagement and quality of life. Consequently, investigating the present status and repercussions on social participation among individuals undergoing MHD has evolved as a crucial area of research. This study aimed to investigate the current status of social participation among patients undergoing MHD and analyse the influencing factors, providing a theoretical basis for clinical intervention.</p><p><strong>Methods: </strong>This cross-sectional study utilised a convenience sampling method to select 441 patients undergoing maintenance haemodialysis (MHD) at seven tertiary hospitals in Lianyungang between January and May 2024 as survey participants. The study employed a general information questionnaire along with several assessment tools, including the Chinese version of the Impact on Participation and Autonomy; Social Support Rating Scale; Hospital Anxiety and Depression Scale; Pittsburgh Sleep Quality Index; Chinese version of the Functional Assessment of Chronic Illness Therapy-Fatigue; and Medical Outcomes Study Health Status Short Form. Patients with end-stage renal disease aged ≥ 18 years and undergoing MHD for ≥ 3 months were included. Those with other severe illnesses, psychiatric disorders, personality disorders, or inability to cooperate with the study were excluded. Multivariate linear regression analysis was used to identify factors influencing social participation in MHD patients.</p><p><strong>Results: </strong>The total score of social participation among patients on MHD was 54. Multiple linear regression analysis indicated that, based on the International Classification of Functioning, Disability, and Health framework, total scores of depression, total scores of social support, age, total scores of the fatigue scale, smoking history, and employment status were the main influencing factors of social participation in patients on MHD (P < 0.05).</p><p><strong>Conclusions: </strong>The level of social participation among patients on MHD was moderate and in need of enhancement. Healthcare providers should prioritise older, unemployed patients and improve their social participation and quality of life by addressing issues such as fatigue, depression, and enhancing social support.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"116"},"PeriodicalIF":2.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}